Mile High Labs

We specialize in water solubility, cannabinoid production, and commercial manufacturing. Let us drive your next brand innovation to new heights of excellence.

[Mile High Labs @MileHighLabs]

https://t.co/aaHnFczYbo

Quick gut check. If a clinician or program operator asked your team:

→ Can you deliver consistent bioavailability across every batch?
→ Is your bioavailability data defensible if someone asks for proof?
→ Can you support oral-only formats at a precise dose?
→ Are you positioned for healthcare-aligned programs now?
→ Are you planning on retrofitting later?
​
How many could you answer?
​
If any of those gave you pause, you're not alone. Most ingredient supply chains were built for a different era, and the standards are shifting fast.
​
We put together a breakdown of what's actually changing and how to evaluate where your team stands.
​
→ See where your supply chain stands
​
The Mile High Labs Global Team

[Mile High Labs @MileHighLabs]

https://t.co/YnEUlq2wql

[Mile High Labs @MileHighLabs]

The announcement has already happened.

What comes next is understanding what it may mean for the future of cannabinoid products.

The Substance Access Beneficiary Engagement Incentive (BEI) is a pilot evaluating physician-supervised, hemp-derived CBD products in a more structured, outcomes-driven environment.

It’s early. It’s limited. And it’s not broad Medicare coverage.

But it does raise an important question for brands:

If cannabinoid products move closer to healthcare-oriented pathways, is your supply chain built for that future?

That’s the conversation we believe is worth having.

Read below in the comments for full blog post.

[Mile High Labs @MileHighLabs]

The Pilot That Could Reshape CBD: A Guide to BEI

[Mile High Labs @MileHighLabs]

CBC 2026 wrapped up with a lot of good conversations, familiar faces, and new connections along the way.

Grateful for everyone who stopped by the booth and took the time to connect with our team throughout the week.

Always interesting to step back and see where the industry is headed—and this year definitely brought a lot of energy and fresh ideas to the conversation.

Until next time. 🍻

[Mile High Labs @MileHighLabs]

We’ve been spending a lot of time lately talking with brewers about what’s next.

CBD beverages keep coming up — not as a trend, but as a new way to expand what’s already working.

We’re heading to Philadelphia next week for the Craft Brewers Conference and looking forward to continuing those conversations in person.

If you’re there, let’s connect.

____________________________

📍 Booth 433 | Craft Brewers Conference | Philadelphia | April 20–22 | @BrewersAssoc

Or feel free to DM us ahead of the show — always happy to start the conversation early.

[Mile High Labs @MileHighLabs]

CBD beverages are showing up in new places — and craft brewers are paying attention.

We’re heading to Philadelphia this April for the Craft Brewers Conference — looking forward to some really good conversations.

CBD beverages are starting to carve out a new space in the craft world — not as a replacement, but as an extension of what brewers already do best: create thoughtful, differentiated experiences.

As that shift continues, the questions we’re hearing are evolving too:
↳ How do you formulate something that actually works in a beverage?
↳ How do you scale it without compromising quality?
↳ How do you navigate what’s next globally?

That’s where we’ve been spending our time.

If you’re attending, come meet Dan Flynn, Heather Salerno, and Vardan Ter-Antonyan — the team working closely with brands to bring these products to life.

No hard pitch — just a chance to connect, share ideas, and talk about where things are heading.

____________________________

📍 Booth 433 | Craft Brewers Conference | Philadelphia | April 20–22

Let’s connect in Philadelphia. Brewers Association

Or feel free to DM us ahead of the show — always happy to start the conversation early.

[Mile High Labs @MileHighLabs]

Some suppliers take orders.

Others keep shelves ready.

CBD and CBG stocked and ready to ship.

[Mile High Labs @MileHighLabs]

Ten years ago, Mile High Labs was founded by Stephen Mueller with a vision to bring science and scale to a growing industry.

From early lab work to an industrial facility in Loveland, Colorado, those first steps helped shape the foundation of what we’ve built today.

Ten years in. Still evolving.

#MileHighLabs #10years

[Mile High Labs @MileHighLabs]

10 years in — and just getting started.

This isn’t just our work.
It’s our life’s work.
Grateful for the journey. Excited for what’s next.

[Mile High Labs @MileHighLabs]

Every January brings a familiar conversation back into focus.

Dry January offers a clearer view into how beverage choice is evolving.

We shared a few thoughts on what this signals for ingredient-led, CBD, and non-alcoholic beverages — and how brands are planning beyond January.

https://t.co/9nO07xSfzn

[Mile High Labs @MileHighLabs]

Consistency doesn’t come from promises — it comes from process.

CBD Isolate 2.0 is manufactured in-house and released across multiple batches, with the same specifications every time.

Going directly to the source helps remove guesswork and keeps standards clear.

#CBDIndustry #IngredientManufacturing #CBDIngredients #SupplyChainTransparency
#B2BManufacturing #QualityFirst #BehindTheScenes
#CannabinoidIndustry #DirectFromTheSource #ManufacturingProcess

[Mile High Labs @MileHighLabs]

2025, by the numbers — built on compliance, quality, and safety.

• 676 million milligrams of water-soluble CBD isolate formulated into beverage brand products
• Shipped globally to 31 countries
• 542% year-over-year growth in CBD 2.0 sales

This progress didn’t come from shortcuts. It came from engineering precision into every ingredient and validating compliance across global markets—from the U.S. to the UK, EU, and Japan.

Thank you for being part of the journey. We’re excited for what’s ahead in 2026.

[Mile High Labs @MileHighLabs]

We’ve had a few conversations this week about what federal rescheduling really means for CBD — especially during a quieter holiday stretch.

This shift isn’t about hype or fast wins.
It’s about governance, scrutiny, and long-term readiness.

Our latest blog walks through what’s changing, what isn’t, and why that distinction matters. 🔗https://t.co/fhmvUCSFeT🔗

[Mile High Labs @MileHighLabs]

Grateful for the moments that bring us together — across teams, time zones, and communities.

As we close out the year, we want to take a moment to say thank you to our partners, collaborators, and colleagues around the world.

Wishing you a wonderful holiday season and a bright start to the new year ahead. From our global team to you. #seasonofthanks #globalcommunity #builtforwhatsnext

https://t.co/RVzS4huePL via @YouTube

[Mile High Labs @MileHighLabs]

CBD hasn’t been held back by demand.

It’s been held back by uncertainty — and by the U.S. federal government largely staying on the sidelines.

That’s why the recent executive order directing the rescheduling of cannabis from Schedule I to Schedule III matters. Not because it’s a wellness moment. Not because it unlocks overnight commercialization.

It matters because it’s a U.S. federal regulatory signal.
It signals that cannabinoids are moving out of limbo and into a phase of active governance and higher scrutiny. And when the U.S. changes posture, global regulators, multinational brands, and product teams pay attention.

The next phase of CBD won’t be driven by lifestyle branding or influencer claims. It will be driven by defensible specs, toxicology data, stability, and systems that can stand up to review across markets.

This is the direction we’ve been building toward at Mile High Labs for years.

We break down what this shift actually means for CBD and regulated markets in our latest blog: CBD Is Entering a Regulated Era — Why Federal Rescheduling Changes the Landscape🔗https://t.co/fhmvUCTd4r🔗

[The White House @WhiteHouse]

President Donald J. Trump signs an Executive Order rescheduling marijuana from Schedule I to Schedule III — recognizing legitimate medical uses and expanding medical marijuana and cannabidiol research to better support patients and doctors.

[Mile High Labs @MileHighLabs]

Built by us. Trusted by you.

During our time in Japan, one message came through clearly: who you source from matters.

Mile High Labs already supplies CBD ingredients into Japan and supports some of the world’s most recognized CBD brands globally. We don’t operate as a middle layer — we manufacture and supply directly, giving partners clarity, control, and confidence from production through global distribution.

Sourcing from the manufacturer isn’t just about efficiency. It’s about:
• Process transparency
• Quality control at every stage
• Clear documentation for regulated markets
• Reduced risk compared to non-manufacturing suppliers

We’ve listened closely to regulators and industry partners. That insight shapes how we innovate, manufacture, and supply CBD Isolate 2.0 — at the source.

Long-term success starts with who builds your ingredient.

[Mile High Labs @MileHighLabs]

Heading to Tokyo? Meet the Mile High Labs team at the Japan International Hemp Expo. #JIHE2025

Compliance, quality, and safety aren’t talking points—they’re the foundation of every ingredient we produce.

As a manufacturer that actually makes its own CBD ingredients, we support top global brands with ISO 17025 testing, NSF GMP manufacturing, and extensive toxicology and stability data. Our CBD Isolate 2.0, CBG Isolate 2.0, and water-soluble formats are built to meet Japan’s strict regulatory standards.

Come see us at JIHE 2025 (Booth C12) and discover how science-driven innovation shapes everything we do.

Our latest blog explores:
✔️ Japan’s evolving CBD and wellness landscape
✔️ Why global partners trust our expertise
✔️ How compliance and science are powering the category’s next chapter

https://t.co/0UIHUIxbfW